## Press Release



## **Dividend Proposal by the Board of Directors**

• Proposed dividend to increase by 50%

Aubagne | Goettingen, March 3, 2011 – At today's meeting, the Board of Directors of Sartorius Stedim Biotech S.A. resolved to submit a proposal to the Annual General Shareholders' Meeting (AGM) on April 18, 2011, to pay a dividend of €0.90 per share for fiscal 2010. Compared with a year earlier, dividends would increase by 50% from €0.60, while the dividend payout ratio would remain at same level (2009: 29.4%; 2010: 30.5%).

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

## A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions".

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs nearly 2,600 people, and in 2010 earned sales revenue of 432.9 million euros.

**Contact:** Petra Kirchhoff; Vice President of Group Corporate Communications; Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany; Phone: +49(0)551/ 308-1686; Fax: +49(0)551/ 308-3410; e-mail: petra.kirchhoff@sartorius.com; www.sartorius-stedim.com Sartorius Stedim Biotech S.A. Z.I. Les Paluds Avenue de Jouques B.P. 1051 13781 Aubagne – France

www.sartorius-stedim.com

Press Contact: Petra Kirchhoff Tel. +49 (0)551.308.1686